Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2017) 49 GP219 | DOI: 10.1530/endoabs.49.GP219

Thyroid 3

Delayed TSH recovery after dose adjustment during TSH-suppressive levothyroxine therapy in patients with differentiated thyroid cancer

Hye In Kim, Tae Hyuk Kim, Young Nam Kim, Hosu Kim, So Young Park, Yun Jae Chung, Jae Hoon Chung & Sun Wook Kim


1Samsung Medical Center, Seoul, Republic of Korea; 2Chung-Ang University Hospital, Seoul, Republic of Korea.

Background: Delayed thyroid-stimulating hormone (TSH) recovery during treatment of Graves’ disease is caused by long-term excessive thyroid hormone, which results in down-regulation of pituitary thyrotropic cells. However, it is unknown whether delayed TSH recovery exists after levothyroxine (LT4) dose adjustment in patients with differentiated thyroid cancer (DTC) who are taking a suppressive dose of LT4.

Methods: We retrospectively reviewed 97 DTC patients who had a reduced LT4 dose while receiving excessive LT4 for TSH suppression. TSH levels at baseline (point 1), 6 months (point 2), and 12-18 months (point 3) after LT4 dose adjustment were compared with each other. A delayed TSH recovery group whose TSH levels exceeded target TSH levels (according to recent guidelines) between points 2 and 3 was identified.

Results: In patients with LT4 reduction, the median TSH level at point 3 was significantly higher than that at point 2 [0.17 vs 0.09 μIU/ml; P<0.001). The delayed TSH recovery group (44.3%, 43 of 97 patients) showed increased body weight during follow-up (60.84–62.73 kg; P=0.01), although TSH levels remained in the target range. A lower LT4 dose per body weight (LT4 dose/weight) after reduction [HR (95% CI), 0.01 (0.00–0.54); P=0.03], greater changes in the LT4 dose/weight [1.10 (1.00–1.22); P=0.04], and higher BMI before surgery [1.19 (1.03–1.38); P=0.01] predicted the occurrence of delayed TSH recovery.

Conclusions: Delayed TSH recovery was commonly observed after LT4 dose adjustment was performed as recommended by dynamic risk stratification. Six months may not be enough time to evaluate real thyroid hormone status by TSH levels.

Volume 49

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts

No recent abstracts.